<DOC>
	<DOC>NCT02022540</DOC>
	<brief_summary>The objective of this study is to assess the safety and tolerability of topical ocular PAN-90806 in patients with active, subfoveal choroidal neovascularization associated with neovascular Age-Related Macular Degeneration (AMD).</brief_summary>
	<brief_title>Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Diagnosis in the study eye of active, pathologic, newly diagnosed and previously untreated, subfoveal choroidal neovascular (CNV) lesions secondary to neovascular AMD Aged 50 years or older Demonstrate the ability, or have a family member who is willing and able, to instill topical ocular drops in the study eye No prior ocular or systemic treatment or surgery for neovascular AMD in the study eye History of or current clinical evidence in the study eye of: aphakia diabetic macular edema any ocular inflammation or infections pathological myopia retinal detachment advanced glaucoma significant media opacity, including cataract History or evidence of the following surgeries in the study eye: penetrating keratoplasty or vitrectomy; corneal transplant; corneal or intraocular surgery within 3 months of Screening Uncontrolled hypertension despite use of antihypertensive medications Participation in any investigational drug or device study, systemic or ocular, within past 3 months Women who are pregnant or nursing Known serious allergies or hypersensitivity to the fluorescein dye used in angiography or to the components of the PAN90806 formulation</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Neovascular Age-Related Macular Degeneration</keyword>
	<keyword>AMD</keyword>
	<keyword>Macular Degeneration</keyword>
	<keyword>Age-Related Macular Degeneration</keyword>
	<keyword>wet AMD</keyword>
	<keyword>neovascular AMD</keyword>
	<keyword>exudative AMD</keyword>
</DOC>